Blog

Nicholas DeVito: Gli2 promotes tumor immune evasion and immunotherapy resistance through Wnt and Prostaglandin signaling

Nicholas DeVito/scholars.duke.edu

Feb 26, 2025, 10:32

Nicholas DeVito: Gli2 promotes tumor immune evasion and immunotherapy resistance through Wnt and Prostaglandin signaling

Nicholas DeVito, Assistant Professor of Medicine at Duke University, Division of Medical Oncology, shared a paper he and his colleagues authored on LinkedIn:

“After 7 years of work our manuscript is published in Cancer Research

Here we describe how the hedgehog pathway transcription factor Gli2 promotes tumor immune evasion and immunotherapy resistance through Wnt and Prostaglandin signaling, which can be overcome with clinical pharmacologic inhibitors.

See the tutorial on BlueSky here.”

Gli2 Facilitates Tumor Immune Evasion and Immunotherapeutic Resistance by Coordinating Wnt Ligand and Prostaglandin Signaling

Authors: Nicholas C DeVito et al.

Nicholas DeVito

Balamayooran Theivanthiran Brent A. Hanks cancer Georgia M. Beasley Kaylee A. Villarreal Michael Aksu Michael P. Plebanek Michael Sturdivant Nagendra Yarla Nicholas C. DeVito OncoDaily Oncology Vaibhav Jain Y-Van Nguyen

Highlights from TTLC2025

KIMMTRAK (Tebentafusp) uses in Cancer: Dosages, Indications, Expectations and more

Senator Edward Markey in Response to OncoDaily About Pediatric Cancer Funding

New Paper Alert: Efficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer